There is no doubt that patients who continue maintenance Revlimid (lenalidomide) following autologous transplant do better than those who do not.  Dr. Phil McCarthy showed unequivocally in CALGB 100104 (Revlimid vs placebo) that progression free survival (PFS) and overall survival (OS) are longer for patients taking maintenance Revlimid.  Likewise, maintenance therapy extends PFS for patients […]